Publications en collaboration avec des chercheurs de Hospital Universitario de la Princesa (16)

2022

  1. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

    Cancers, Vol. 14, Núm. 7

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

2017

  1. Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials

    Journal of Clinical Oncology, Vol. 35, Núm. 25, pp. 2900-2910

  2. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

    Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation

    Bone Marrow Transplantation, Vol. 51, Núm. 1, pp. 79-82

2015

  1. Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT

    Bone Marrow Transplantation

  2. The genotype of the donor for the (GT)n polymorphism in the promoter/enhancer of FOXP3 Is associated with the development of severe acute GVHD but does not affect the GVL effect after myeloablative HLA-Identical allogeneic stem cell transplantation

    PLoS ONE, Vol. 10, Núm. 10

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

  2. Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)

    Leukemia and Lymphoma, Vol. 55, Núm. 5, pp. 1007-1012

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

    Annals of Hematology, Vol. 92, Núm. 9, pp. 1151-1179

2012

  1. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Blood, Vol. 119, Núm. 3, pp. 687-691

  2. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

2005

  1. Minor histocompatibility antigen HA-8 mismatch and clinical outcome after hla-identical sibling donor allogeneic stem cell transplantation

    Haematologica, Vol. 90, Núm. 12, pp. 1723-1724

2001

  1. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation

    British Journal of Haematology, Vol. 114, Núm. 4, pp. 931-936